Cargando…

Difficulties in Diagnosing Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy (LVH): Is the Novel GLA Gene Mutation a Pathogenic Mutation or Polymorphism?

Fabry disease (FD) is an X-linked, lysosomal glycosphingolipid storage disorder that occurs very rarely. Cardiac involvement may comprise of left ventricular hypertrophy (LVH), arrhythmias, conduction abnormalities, heart failure and valvular abnormalities. The goal of this study was to conduct gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aladağ, N, Ali Barman, H, Şipal, A, Akbulut, T, Özdemir, M, Ceylaner, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413883/ https://www.ncbi.nlm.nih.gov/pubmed/37576794 http://dx.doi.org/10.2478/bjmg-2023-0010

Ejemplares similares

p.R220L Is a Likely Pathogenic Novel GLA Gene Mutation Responsible for Fabry Disease
por: Ali Barman, Hasan, et al.
Publicado: (2022)

Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy
por: Sadasivan, Chandu, et al.
Publicado: (2020)

Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation
por: Chien, Yueh, et al.
Publicado: (2016)

Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022)

Unexplained Left Ventricular Hypertrophy Diagnosed as a Cardiac Variant of Late-Onset Fabry Disease: A Case Report
por: Zhao, Maomao, et al.
Publicado: (2023)

Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
por: Baptista, Ana, et al.
Publicado: (2015)

Fabry disease due to D313Y and novel GLA mutations
por: Koulousios, Konstantinos, et al.
Publicado: (2017)

Functional evaluation of a novel GLA causative mutation in Fabry disease
por: Li, Ping, et al.
Publicado: (2019)

Novel GLA Mutation Promotes Intron Inclusion Leading to Fabry Disease
por: Varela, Patrícia, et al.
Publicado: (2019)

Correction: Fabry disease due to D313Y and novel GLA mutations
Publicado: (2018)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
por: Chaves-Markman, Ândrea Virgínia, et al.
Publicado: (2019)

Abnormal Pre-mRNA Splicing in Exonic Fabry Disease-Causing GLA Mutations
por: Alfen, Franziska, et al.
Publicado: (2022)

The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges
por: BoonPeng, Hoh, et al.
Publicado: (2013)

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
por: Brown, Alexander J M, et al.
Publicado: (2020)

Assessment of Left Ventricular Hypertrophy (LVH) Criteria by Surface Electrocardiography in a Sample of Iraqi Patients with Systemic Arterial Hypertension
por: Altaweel, Rafid Bashir, et al.
Publicado: (2020)

Renal variant of Fabry disease with sporadic GLA gene mutation: role of early renal biopsy
por: Al-Salam, Suhail, et al.
Publicado: (2012)

Identification of a Novel GLA Mutation (L206 P) in a Patient with Fabry Disease
por: Kim, Ji-Hoon, et al.
Publicado: (2017)

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation
por: Valtola, Kati, et al.
Publicado: (2023)

ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
por: Kozor, Rebecca, et al.
Publicado: (2016)

The association between annexin A5 (ANXA5) gene polymorphism and left ventricular hypertrophy (LVH) in Chinese endogenous hypertension patients
por: Zhang, Bei, et al.
Publicado: (2017)

Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy
por: Kim, Woo-Shik, et al.
Publicado: (2019)

Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease
por: Zhou, Chi, et al.
Publicado: (2018)

Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis
por: Yousef, Zaheer, et al.
Publicado: (2013)

Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey
por: Barman, Hasan Ali, et al.
Publicado: (2020)

Identification of a novel GLA mutation (F69 L) in a Japanese patient with late-onset Fabry disease
por: Umeda, Toshiko, et al.
Publicado: (2015)

Fabry disease: Evidence for a regional founder effect of the GLA gene mutation 30delG in Brazilian patients
por: de Alencar, Dayse Oliveira, et al.
Publicado: (2014)

Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA
por: Massera, Daniele, et al.
Publicado: (2019)

Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study
por: Germain, Dominique P., et al.
Publicado: (2018)

A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report
por: Pisani, Antonio, et al.
Publicado: (2012)

Identification of a novel GLA mutation (Y88C) in a Korean family with Fabry nephropathy: a case report
por: Chong, Yosep, et al.
Publicado: (2016)

Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype
por: Choi, Jin-Ho, et al.
Publicado: (2017)

Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A)
por: Hsu, Ting-Rong, et al.
Publicado: (2014)

Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study　― Protocol for a Multicenter, Open-Label, Exploratory Interventional Study ―
por: Sueta, Daisuke, et al.
Publicado: (2022)

Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery
por: Porcari, Aldostefano, et al.
Publicado: (2021)

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)

Mono-symptomatic Fabry disease in a population with mild-to-moderate left ventricular hypertrophy
por: Fuller, Maria, et al.
Publicado: (2020)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

Rare Etiology of Renal Failure in a 25-Year-Old Caucasian Man: Fabry Disease With a Novel Mutation of GLA Gene
por: Gaballa, Salem, et al.
Publicado: (2020)

Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease
por: Dai, Xuantong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nre6utsu11h2chkiqsfj4uq55m